nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—bone cancer—brain cancer	0.325	0.558	CtDrD
Methotrexate—germ cell cancer—brain cancer	0.258	0.443	CtDrD
Methotrexate—ABCC10—Etoposide—brain cancer	0.0579	0.303	CbGbCtD
Methotrexate—ABCC3—Etoposide—brain cancer	0.0364	0.191	CbGbCtD
Methotrexate—ABCC1—Etoposide—brain cancer	0.0224	0.117	CbGbCtD
Methotrexate—ABCC2—Carboplatin—brain cancer	0.0197	0.103	CbGbCtD
Methotrexate—ABCG2—Carboplatin—brain cancer	0.0178	0.0932	CbGbCtD
Methotrexate—ABCC2—Etoposide—brain cancer	0.0166	0.0866	CbGbCtD
Methotrexate—ABCG2—Etoposide—brain cancer	0.015	0.0783	CbGbCtD
Methotrexate—ABCB1—Etoposide—brain cancer	0.0054	0.0282	CbGbCtD
Methotrexate—SLC22A8—choroid plexus—brain cancer	0.00328	0.0608	CbGeAlD
Methotrexate—ATIC—ganglion—brain cancer	0.00131	0.0243	CbGeAlD
Methotrexate—SLCO1C1—ganglion—brain cancer	0.00109	0.0202	CbGeAlD
Methotrexate—MTHFR—ganglion—brain cancer	0.000975	0.0181	CbGeAlD
Methotrexate—MTHFR—blood vessel—brain cancer	0.000775	0.0144	CbGeAlD
Methotrexate—TYMS—Podofilox—Etoposide—brain cancer	0.000766	1	CbGdCrCtD
Methotrexate—FOLR1—pituitary gland—brain cancer	0.000729	0.0135	CbGeAlD
Methotrexate—ABCC11—gonad—brain cancer	0.000717	0.0133	CbGeAlD
Methotrexate—SLC19A1—gonad—brain cancer	0.000655	0.0122	CbGeAlD
Methotrexate—GGH—telencephalon—brain cancer	0.000595	0.011	CbGeAlD
Methotrexate—ATIC—brainstem—brain cancer	0.00057	0.0106	CbGeAlD
Methotrexate—FOLR1—endocrine gland—brain cancer	0.000565	0.0105	CbGeAlD
Methotrexate—FOLR1—head—brain cancer	0.000558	0.0104	CbGeAlD
Methotrexate—ABCC11—endocrine gland—brain cancer	0.000542	0.0101	CbGeAlD
Methotrexate—FOLR1—central nervous system—brain cancer	0.000509	0.00945	CbGeAlD
Methotrexate—ATIC—telencephalon—brain cancer	0.000506	0.00939	CbGeAlD
Methotrexate—FOLR1—cerebellum—brain cancer	0.000497	0.00923	CbGeAlD
Methotrexate—GGH—gonad—brain cancer	0.000497	0.00922	CbGeAlD
Methotrexate—SLC19A1—endocrine gland—brain cancer	0.000495	0.00919	CbGeAlD
Methotrexate—SLC46A1—pituitary gland—brain cancer	0.000493	0.00914	CbGeAlD
Methotrexate—SLC19A1—head—brain cancer	0.000489	0.00908	CbGeAlD
Methotrexate—GGH—pituitary gland—brain cancer	0.000485	0.00899	CbGeAlD
Methotrexate—GGH—medulla oblongata—brain cancer	0.000468	0.00868	CbGeAlD
Methotrexate—SLC19A1—central nervous system—brain cancer	0.000446	0.00828	CbGeAlD
Methotrexate—SLC19A1—cerebellum—brain cancer	0.000436	0.0081	CbGeAlD
Methotrexate—GGH—midbrain—brain cancer	0.000427	0.00793	CbGeAlD
Methotrexate—FPGS—pituitary gland—brain cancer	0.000426	0.00791	CbGeAlD
Methotrexate—SLC46A1—spinal cord—brain cancer	0.000424	0.00787	CbGeAlD
Methotrexate—ATIC—gonad—brain cancer	0.000422	0.00784	CbGeAlD
Methotrexate—SLCO1C1—telencephalon—brain cancer	0.000421	0.00781	CbGeAlD
Methotrexate—SLCO1B3—pituitary gland—brain cancer	0.000418	0.00775	CbGeAlD
Methotrexate—GGH—spinal cord—brain cancer	0.000417	0.00774	CbGeAlD
Methotrexate—FPGS—medulla oblongata—brain cancer	0.000411	0.00763	CbGeAlD
Methotrexate—FOLR1—brain—brain cancer	0.000404	0.0075	CbGeAlD
Methotrexate—SLC46A1—endocrine gland—brain cancer	0.000382	0.00708	CbGeAlD
Methotrexate—SLC46A1—head—brain cancer	0.000377	0.00699	CbGeAlD
Methotrexate—MTHFR—telencephalon—brain cancer	0.000376	0.00698	CbGeAlD
Methotrexate—GGH—endocrine gland—brain cancer	0.000375	0.00697	CbGeAlD
Methotrexate—GGH—head—brain cancer	0.000371	0.00688	CbGeAlD
Methotrexate—FPGS—spinal cord—brain cancer	0.000367	0.0068	CbGeAlD
Methotrexate—ATIC—midbrain—brain cancer	0.000363	0.00675	CbGeAlD
Methotrexate—ATIC—spinal cord—brain cancer	0.000355	0.00658	CbGeAlD
Methotrexate—SLC19A1—brain—brain cancer	0.000354	0.00658	CbGeAlD
Methotrexate—SLC46A1—central nervous system—brain cancer	0.000344	0.00638	CbGeAlD
Methotrexate—TYMS—telencephalon—brain cancer	0.000343	0.00637	CbGeAlD
Methotrexate—SLCO1C1—pituitary gland—brain cancer	0.000343	0.00636	CbGeAlD
Methotrexate—DHFR—telencephalon—brain cancer	0.00034	0.00631	CbGeAlD
Methotrexate—GGH—central nervous system—brain cancer	0.000338	0.00628	CbGeAlD
Methotrexate—SLC46A1—cerebellum—brain cancer	0.000336	0.00624	CbGeAlD
Methotrexate—GGH—cerebellum—brain cancer	0.000331	0.00614	CbGeAlD
Methotrexate—FPGS—endocrine gland—brain cancer	0.00033	0.00613	CbGeAlD
Methotrexate—PGD—telencephalon—brain cancer	0.000327	0.00606	CbGeAlD
Methotrexate—FPGS—head—brain cancer	0.000326	0.00605	CbGeAlD
Methotrexate—SLCO1B3—endocrine gland—brain cancer	0.000324	0.00601	CbGeAlD
Methotrexate—ATIC—endocrine gland—brain cancer	0.000319	0.00592	CbGeAlD
Methotrexate—ATIC—head—brain cancer	0.000315	0.00585	CbGeAlD
Methotrexate—SLCO3A1—gonad—brain cancer	0.000309	0.00573	CbGeAlD
Methotrexate—SLC16A1—telencephalon—brain cancer	0.000305	0.00566	CbGeAlD
Methotrexate—SLCO1C1—midbrain—brain cancer	0.000302	0.00561	CbGeAlD
Methotrexate—SLCO3A1—pituitary gland—brain cancer	0.000301	0.00559	CbGeAlD
Methotrexate—FPGS—central nervous system—brain cancer	0.000297	0.00552	CbGeAlD
Methotrexate—SLCO1C1—spinal cord—brain cancer	0.000295	0.00547	CbGeAlD
Methotrexate—SLCO3A1—medulla oblongata—brain cancer	0.000291	0.0054	CbGeAlD
Methotrexate—FPGS—cerebellum—brain cancer	0.000291	0.0054	CbGeAlD
Methotrexate—ATIC—central nervous system—brain cancer	0.000288	0.00534	CbGeAlD
Methotrexate—TYMS—gonad—brain cancer	0.000286	0.00532	CbGeAlD
Methotrexate—DHFR—gonad—brain cancer	0.000284	0.00526	CbGeAlD
Methotrexate—ATIC—cerebellum—brain cancer	0.000281	0.00522	CbGeAlD
Methotrexate—ABCC10—telencephalon—brain cancer	0.00028	0.0052	CbGeAlD
Methotrexate—DHFR—pituitary gland—brain cancer	0.000277	0.00514	CbGeAlD
Methotrexate—SLC46A1—brain—brain cancer	0.000273	0.00507	CbGeAlD
Methotrexate—PGD—gonad—brain cancer	0.000273	0.00506	CbGeAlD
Methotrexate—GGH—brain—brain cancer	0.000269	0.00498	CbGeAlD
Methotrexate—DHFR—medulla oblongata—brain cancer	0.000267	0.00496	CbGeAlD
Methotrexate—PGD—pituitary gland—brain cancer	0.000266	0.00494	CbGeAlD
Methotrexate—SLCO3A1—midbrain—brain cancer	0.000266	0.00493	CbGeAlD
Methotrexate—SLCO1C1—endocrine gland—brain cancer	0.000265	0.00493	CbGeAlD
Methotrexate—SLCO1C1—head—brain cancer	0.000262	0.00486	CbGeAlD
Methotrexate—SLCO3A1—spinal cord—brain cancer	0.000259	0.00481	CbGeAlD
Methotrexate—SLC22A11—endocrine gland—brain cancer	0.000258	0.00478	CbGeAlD
Methotrexate—PGD—medulla oblongata—brain cancer	0.000257	0.00476	CbGeAlD
Methotrexate—SLC16A1—gonad—brain cancer	0.000255	0.00472	CbGeAlD
Methotrexate—SLC22A7—endocrine gland—brain cancer	0.000252	0.00467	CbGeAlD
Methotrexate—SLC16A1—pituitary gland—brain cancer	0.000248	0.00461	CbGeAlD
Methotrexate—TYMS—midbrain—brain cancer	0.000246	0.00457	CbGeAlD
Methotrexate—DHFR—midbrain—brain cancer	0.000244	0.00453	CbGeAlD
Methotrexate—SLCO1A2—telencephalon—brain cancer	0.000241	0.00448	CbGeAlD
Methotrexate—AOX1—gonad—brain cancer	0.00024	0.00446	CbGeAlD
Methotrexate—SLC16A1—medulla oblongata—brain cancer	0.00024	0.00445	CbGeAlD
Methotrexate—SLCO1C1—central nervous system—brain cancer	0.000239	0.00444	CbGeAlD
Methotrexate—DHFR—spinal cord—brain cancer	0.000238	0.00442	CbGeAlD
Methotrexate—MTHFR—endocrine gland—brain cancer	0.000237	0.0044	CbGeAlD
Methotrexate—FPGS—brain—brain cancer	0.000236	0.00438	CbGeAlD
Methotrexate—PGD—midbrain—brain cancer	0.000235	0.00435	CbGeAlD
Methotrexate—AOX1—pituitary gland—brain cancer	0.000234	0.00435	CbGeAlD
Methotrexate—MTHFR—head—brain cancer	0.000234	0.00435	CbGeAlD
Methotrexate—ABCC10—gonad—brain cancer	0.000234	0.00434	CbGeAlD
Methotrexate—SLCO3A1—endocrine gland—brain cancer	0.000233	0.00433	CbGeAlD
Methotrexate—SLCO3A1—head—brain cancer	0.00023	0.00428	CbGeAlD
Methotrexate—PGD—spinal cord—brain cancer	0.000229	0.00425	CbGeAlD
Methotrexate—ATIC—brain—brain cancer	0.000228	0.00424	CbGeAlD
Methotrexate—ABCC10—pituitary gland—brain cancer	0.000228	0.00423	CbGeAlD
Methotrexate—ABCC10—medulla oblongata—brain cancer	0.00022	0.00409	CbGeAlD
Methotrexate—SLC16A1—midbrain—brain cancer	0.000219	0.00407	CbGeAlD
Methotrexate—TYMS—endocrine gland—brain cancer	0.000216	0.00402	CbGeAlD
Methotrexate—DHFR—endocrine gland—brain cancer	0.000214	0.00398	CbGeAlD
Methotrexate—MTHFR—central nervous system—brain cancer	0.000214	0.00397	CbGeAlD
Methotrexate—TYMS—head—brain cancer	0.000214	0.00397	CbGeAlD
Methotrexate—SLC16A1—spinal cord—brain cancer	0.000214	0.00397	CbGeAlD
Methotrexate—DHFR—head—brain cancer	0.000212	0.00393	CbGeAlD
Methotrexate—SLCO3A1—central nervous system—brain cancer	0.00021	0.0039	CbGeAlD
Methotrexate—MTHFR—cerebellum—brain cancer	0.000209	0.00388	CbGeAlD
Methotrexate—PGD—endocrine gland—brain cancer	0.000206	0.00382	CbGeAlD
Methotrexate—SLCO3A1—cerebellum—brain cancer	0.000206	0.00382	CbGeAlD
Methotrexate—PGD—head—brain cancer	0.000203	0.00378	CbGeAlD
Methotrexate—ABCC10—midbrain—brain cancer	0.000201	0.00373	CbGeAlD
Methotrexate—ABCC1—telencephalon—brain cancer	0.000198	0.00368	CbGeAlD
Methotrexate—ABCC10—spinal cord—brain cancer	0.000196	0.00364	CbGeAlD
Methotrexate—TYMS—central nervous system—brain cancer	0.000195	0.00362	CbGeAlD
Methotrexate—DHFR—central nervous system—brain cancer	0.000193	0.00358	CbGeAlD
Methotrexate—SLC16A1—endocrine gland—brain cancer	0.000192	0.00357	CbGeAlD
Methotrexate—TYMS—cerebellum—brain cancer	0.000191	0.00354	CbGeAlD
Methotrexate—SLC16A1—head—brain cancer	0.00019	0.00352	CbGeAlD
Methotrexate—SLCO1C1—brain—brain cancer	0.00019	0.00352	CbGeAlD
Methotrexate—SLCO1A2—medulla oblongata—brain cancer	0.00019	0.00352	CbGeAlD
Methotrexate—DHFR—cerebellum—brain cancer	0.000189	0.0035	CbGeAlD
Methotrexate—SLCO1B1—endocrine gland—brain cancer	0.000187	0.00347	CbGeAlD
Methotrexate—PGD—central nervous system—brain cancer	0.000186	0.00345	CbGeAlD
Methotrexate—AOX1—endocrine gland—brain cancer	0.000182	0.00337	CbGeAlD
Methotrexate—PGD—cerebellum—brain cancer	0.000181	0.00337	CbGeAlD
Methotrexate—SLC22A7—brain—brain cancer	0.00018	0.00334	CbGeAlD
Methotrexate—ABCC3—endocrine gland—brain cancer	0.000178	0.0033	CbGeAlD
Methotrexate—ABCC10—endocrine gland—brain cancer	0.000177	0.00328	CbGeAlD
Methotrexate—ABCC3—head—brain cancer	0.000175	0.00325	CbGeAlD
Methotrexate—SLC22A6—brain—brain cancer	0.000174	0.00323	CbGeAlD
Methotrexate—SLCO1A2—midbrain—brain cancer	0.000173	0.00322	CbGeAlD
Methotrexate—SLC16A1—central nervous system—brain cancer	0.000173	0.00322	CbGeAlD
Methotrexate—MTHFR—brain—brain cancer	0.00017	0.00315	CbGeAlD
Methotrexate—SLC16A1—cerebellum—brain cancer	0.000169	0.00314	CbGeAlD
Methotrexate—SLCO1A2—spinal cord—brain cancer	0.000169	0.00314	CbGeAlD
Methotrexate—SLCO3A1—brain—brain cancer	0.000167	0.0031	CbGeAlD
Methotrexate—ABCB1—blood vessel—brain cancer	0.000167	0.00309	CbGeAlD
Methotrexate—ABCG2—telencephalon—brain cancer	0.000164	0.00304	CbGeAlD
Methotrexate—ABCC1—pituitary gland—brain cancer	0.000161	0.00299	CbGeAlD
Methotrexate—ABCC3—central nervous system—brain cancer	0.00016	0.00297	CbGeAlD
Methotrexate—AOX1—cerebellum—brain cancer	0.00016	0.00297	CbGeAlD
Methotrexate—ABCC10—cerebellum—brain cancer	0.000156	0.00289	CbGeAlD
Methotrexate—TYMS—brain—brain cancer	0.000155	0.00287	CbGeAlD
Methotrexate—DHFR—brain—brain cancer	0.000153	0.00285	CbGeAlD
Methotrexate—SLCO1A2—endocrine gland—brain cancer	0.000152	0.00283	CbGeAlD
Methotrexate—SLCO1A2—head—brain cancer	0.00015	0.00279	CbGeAlD
Methotrexate—PGD—brain—brain cancer	0.000147	0.00274	CbGeAlD
Methotrexate—ABCC4—endocrine gland—brain cancer	0.000147	0.00272	CbGeAlD
Methotrexate—ABCC4—head—brain cancer	0.000145	0.00269	CbGeAlD
Methotrexate—SLC22A8—head—brain cancer	0.000144	0.00266	CbGeAlD
Methotrexate—ABCC2—endocrine gland—brain cancer	0.000142	0.00263	CbGeAlD
Methotrexate—SLC16A1—brain—brain cancer	0.000138	0.00255	CbGeAlD
Methotrexate—SLCO1A2—central nervous system—brain cancer	0.000137	0.00255	CbGeAlD
Methotrexate—SLCO1A2—cerebellum—brain cancer	0.000134	0.00249	CbGeAlD
Methotrexate—ABCG2—pituitary gland—brain cancer	0.000134	0.00248	CbGeAlD
Methotrexate—ABCC4—central nervous system—brain cancer	0.000132	0.00245	CbGeAlD
Methotrexate—SLC22A8—central nervous system—brain cancer	0.000131	0.00243	CbGeAlD
Methotrexate—AOX1—brain—brain cancer	0.00013	0.00241	CbGeAlD
Methotrexate—ABCG2—medulla oblongata—brain cancer	0.000129	0.00239	CbGeAlD
Methotrexate—ABCC3—brain—brain cancer	0.000127	0.00236	CbGeAlD
Methotrexate—ABCC10—brain—brain cancer	0.000126	0.00235	CbGeAlD
Methotrexate—Confusional state—Procarbazine—brain cancer	0.000119	0.000906	CcSEcCtD
Methotrexate—Vomiting—Lomustine—brain cancer	0.000118	0.0009	CcSEcCtD
Methotrexate—ABCG2—midbrain—brain cancer	0.000118	0.00219	CbGeAlD
Methotrexate—Dysuria—Temozolomide—brain cancer	0.000117	0.000893	CcSEcCtD
Methotrexate—Neutropenia—Temozolomide—brain cancer	0.000117	0.000893	CcSEcCtD
Methotrexate—Infection—Procarbazine—brain cancer	0.000117	0.000892	CcSEcCtD
Methotrexate—Angiopathy—Hydroxyurea—brain cancer	0.000117	0.000888	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Temozolomide—brain cancer	0.000117	0.000888	CcSEcCtD
Methotrexate—Pneumonia—Carmustine—brain cancer	0.000117	0.000886	CcSEcCtD
Methotrexate—Erectile dysfunction—Temozolomide—brain cancer	0.000116	0.00088	CcSEcCtD
Methotrexate—Thrombocytopenia—Procarbazine—brain cancer	0.000116	0.000879	CcSEcCtD
Methotrexate—Depression—Carmustine—brain cancer	0.000116	0.000879	CcSEcCtD
Methotrexate—Chills—Hydroxyurea—brain cancer	0.000115	0.000878	CcSEcCtD
Methotrexate—ABCG2—spinal cord—brain cancer	0.000115	0.00213	CbGeAlD
Methotrexate—Photosensitivity reaction—Temozolomide—brain cancer	0.000115	0.000872	CcSEcCtD
Methotrexate—Hyperhidrosis—Procarbazine—brain cancer	0.000114	0.000868	CcSEcCtD
Methotrexate—Renal failure—Carmustine—brain cancer	0.000114	0.000866	CcSEcCtD
Methotrexate—Alopecia—Hydroxyurea—brain cancer	0.000114	0.000865	CcSEcCtD
Methotrexate—Stomatitis—Carmustine—brain cancer	0.000113	0.000859	CcSEcCtD
Methotrexate—Pneumonia—Temozolomide—brain cancer	0.000113	0.000856	CcSEcCtD
Methotrexate—Anorexia—Procarbazine—brain cancer	0.000113	0.000856	CcSEcCtD
Methotrexate—Erythema—Hydroxyurea—brain cancer	0.000112	0.000852	CcSEcCtD
Methotrexate—Infestation NOS—Temozolomide—brain cancer	0.000112	0.000852	CcSEcCtD
Methotrexate—Infestation—Temozolomide—brain cancer	0.000112	0.000852	CcSEcCtD
Methotrexate—Depression—Temozolomide—brain cancer	0.000112	0.000849	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Temozolomide—brain cancer	0.000111	0.000844	CcSEcCtD
Methotrexate—Nausea—Lomustine—brain cancer	0.00011	0.00084	CcSEcCtD
Methotrexate—Hypotension—Procarbazine—brain cancer	0.00011	0.000839	CcSEcCtD
Methotrexate—ABCC1—cerebellum—brain cancer	0.00011	0.00204	CbGeAlD
Methotrexate—Stomatitis—Temozolomide—brain cancer	0.000109	0.00083	CcSEcCtD
Methotrexate—SLCO1A2—brain—brain cancer	0.000109	0.00202	CbGeAlD
Methotrexate—ALB—brain—brain cancer	0.000108	0.00201	CbGeAlD
Methotrexate—Musculoskeletal discomfort—Procarbazine—brain cancer	0.000108	0.000818	CcSEcCtD
Methotrexate—Insomnia—Procarbazine—brain cancer	0.000107	0.000812	CcSEcCtD
Methotrexate—Paraesthesia—Procarbazine—brain cancer	0.000106	0.000807	CcSEcCtD
Methotrexate—Hepatobiliary disease—Temozolomide—brain cancer	0.000106	0.000805	CcSEcCtD
Methotrexate—Somnolence—Procarbazine—brain cancer	0.000105	0.000799	CcSEcCtD
Methotrexate—ABCC4—brain—brain cancer	0.000105	0.00195	CbGeAlD
Methotrexate—Toxic epidermal necrolysis—Etoposide—brain cancer	0.000105	0.000796	CcSEcCtD
Methotrexate—Haemoglobin—Carmustine—brain cancer	0.000105	0.000795	CcSEcCtD
Methotrexate—SLC22A8—brain—brain cancer	0.000104	0.00193	CbGeAlD
Methotrexate—Haemorrhage—Carmustine—brain cancer	0.000104	0.000791	CcSEcCtD
Methotrexate—Ill-defined disorder—Hydroxyurea—brain cancer	0.000104	0.00079	CcSEcCtD
Methotrexate—Anaemia—Hydroxyurea—brain cancer	0.000104	0.000787	CcSEcCtD
Methotrexate—Decreased appetite—Procarbazine—brain cancer	0.000103	0.000781	CcSEcCtD
Methotrexate—Fatigue—Procarbazine—brain cancer	0.000102	0.000774	CcSEcCtD
Methotrexate—Haemoglobin—Temozolomide—brain cancer	0.000101	0.000768	CcSEcCtD
Methotrexate—Malaise—Hydroxyurea—brain cancer	0.000101	0.000768	CcSEcCtD
Methotrexate—Pain—Procarbazine—brain cancer	0.000101	0.000768	CcSEcCtD
Methotrexate—Hepatitis—Temozolomide—brain cancer	0.000101	0.000764	CcSEcCtD
Methotrexate—Haemorrhage—Temozolomide—brain cancer	0.000101	0.000764	CcSEcCtD
Methotrexate—Leukopenia—Hydroxyurea—brain cancer	0.0001	0.000762	CcSEcCtD
Methotrexate—Visual impairment—Carmustine—brain cancer	0.0001	0.000762	CcSEcCtD
Methotrexate—Pharyngitis—Temozolomide—brain cancer	9.98e-05	0.000759	CcSEcCtD
Methotrexate—Urinary tract disorder—Temozolomide—brain cancer	9.93e-05	0.000755	CcSEcCtD
Methotrexate—Urethral disorder—Temozolomide—brain cancer	9.85e-05	0.000749	CcSEcCtD
Methotrexate—Feeling abnormal—Procarbazine—brain cancer	9.73e-05	0.00074	CcSEcCtD
Methotrexate—Eye disorder—Carmustine—brain cancer	9.72e-05	0.000739	CcSEcCtD
Methotrexate—Convulsion—Hydroxyurea—brain cancer	9.7e-05	0.000738	CcSEcCtD
Methotrexate—Visual impairment—Temozolomide—brain cancer	9.69e-05	0.000737	CcSEcCtD
Methotrexate—Gastrointestinal pain—Procarbazine—brain cancer	9.66e-05	0.000735	CcSEcCtD
Methotrexate—Pancytopenia—Etoposide—brain cancer	9.54e-05	0.000726	CcSEcCtD
Methotrexate—Erythema multiforme—Temozolomide—brain cancer	9.5e-05	0.000723	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	9.47e-05	0.00072	CcSEcCtD
Methotrexate—Discomfort—Hydroxyurea—brain cancer	9.42e-05	0.000716	CcSEcCtD
Methotrexate—Neutropenia—Etoposide—brain cancer	9.4e-05	0.000715	CcSEcCtD
Methotrexate—Eye disorder—Temozolomide—brain cancer	9.39e-05	0.000714	CcSEcCtD
Methotrexate—Urticaria—Procarbazine—brain cancer	9.38e-05	0.000714	CcSEcCtD
Methotrexate—Tinnitus—Temozolomide—brain cancer	9.37e-05	0.000713	CcSEcCtD
Methotrexate—Abdominal pain—Procarbazine—brain cancer	9.34e-05	0.00071	CcSEcCtD
Methotrexate—Body temperature increased—Procarbazine—brain cancer	9.34e-05	0.00071	CcSEcCtD
Methotrexate—Cardiac disorder—Temozolomide—brain cancer	9.33e-05	0.000709	CcSEcCtD
Methotrexate—Alopecia—Carmustine—brain cancer	9.19e-05	0.000699	CcSEcCtD
Methotrexate—Angiopathy—Temozolomide—brain cancer	9.12e-05	0.000694	CcSEcCtD
Methotrexate—Mental disorder—Carmustine—brain cancer	9.11e-05	0.000693	CcSEcCtD
Methotrexate—ABCG2—cerebellum—brain cancer	9.11e-05	0.00169	CbGeAlD
Methotrexate—Infection—Hydroxyurea—brain cancer	9.08e-05	0.000691	CcSEcCtD
Methotrexate—Immune system disorder—Temozolomide—brain cancer	9.08e-05	0.00069	CcSEcCtD
Methotrexate—Mediastinal disorder—Temozolomide—brain cancer	9.06e-05	0.000689	CcSEcCtD
Methotrexate—Malnutrition—Carmustine—brain cancer	9.05e-05	0.000689	CcSEcCtD
Methotrexate—Erythema—Carmustine—brain cancer	9.05e-05	0.000689	CcSEcCtD
Methotrexate—Chills—Temozolomide—brain cancer	9.02e-05	0.000686	CcSEcCtD
Methotrexate—Pneumonia—Etoposide—brain cancer	9.01e-05	0.000685	CcSEcCtD
Methotrexate—Nervous system disorder—Hydroxyurea—brain cancer	8.96e-05	0.000682	CcSEcCtD
Methotrexate—Infestation—Etoposide—brain cancer	8.96e-05	0.000681	CcSEcCtD
Methotrexate—Infestation NOS—Etoposide—brain cancer	8.96e-05	0.000681	CcSEcCtD
Methotrexate—Thrombocytopenia—Hydroxyurea—brain cancer	8.95e-05	0.000681	CcSEcCtD
Methotrexate—ABCC1—brain—brain cancer	8.94e-05	0.00166	CbGeAlD
Methotrexate—Stevens-Johnson syndrome—Etoposide—brain cancer	8.88e-05	0.000676	CcSEcCtD
Methotrexate—Alopecia—Temozolomide—brain cancer	8.88e-05	0.000675	CcSEcCtD
Methotrexate—Skin disorder—Hydroxyurea—brain cancer	8.88e-05	0.000675	CcSEcCtD
Methotrexate—Renal failure—Etoposide—brain cancer	8.81e-05	0.00067	CcSEcCtD
Methotrexate—Mental disorder—Temozolomide—brain cancer	8.81e-05	0.00067	CcSEcCtD
Methotrexate—Back pain—Carmustine—brain cancer	8.76e-05	0.000666	CcSEcCtD
Methotrexate—Erythema—Temozolomide—brain cancer	8.75e-05	0.000665	CcSEcCtD
Methotrexate—Malnutrition—Temozolomide—brain cancer	8.75e-05	0.000665	CcSEcCtD
Methotrexate—Stomatitis—Etoposide—brain cancer	8.73e-05	0.000664	CcSEcCtD
Methotrexate—Anorexia—Hydroxyurea—brain cancer	8.71e-05	0.000663	CcSEcCtD
Methotrexate—Hypersensitivity—Procarbazine—brain cancer	8.7e-05	0.000662	CcSEcCtD
Methotrexate—Dysgeusia—Temozolomide—brain cancer	8.57e-05	0.000652	CcSEcCtD
Methotrexate—Vision blurred—Carmustine—brain cancer	8.53e-05	0.000649	CcSEcCtD
Methotrexate—Asthenia—Procarbazine—brain cancer	8.47e-05	0.000644	CcSEcCtD
Methotrexate—Hepatobiliary disease—Etoposide—brain cancer	8.47e-05	0.000644	CcSEcCtD
Methotrexate—Back pain—Temozolomide—brain cancer	8.46e-05	0.000644	CcSEcCtD
Methotrexate—Anaemia—Carmustine—brain cancer	8.37e-05	0.000636	CcSEcCtD
Methotrexate—Agranulocytosis—Etoposide—brain cancer	8.36e-05	0.000636	CcSEcCtD
Methotrexate—Pruritus—Procarbazine—brain cancer	8.36e-05	0.000636	CcSEcCtD
Methotrexate—Vision blurred—Temozolomide—brain cancer	8.25e-05	0.000627	CcSEcCtD
Methotrexate—Dyspnoea—Hydroxyurea—brain cancer	8.15e-05	0.00062	CcSEcCtD
Methotrexate—Somnolence—Hydroxyurea—brain cancer	8.13e-05	0.000618	CcSEcCtD
Methotrexate—Ill-defined disorder—Temozolomide—brain cancer	8.12e-05	0.000617	CcSEcCtD
Methotrexate—Leukopenia—Carmustine—brain cancer	8.1e-05	0.000616	CcSEcCtD
Methotrexate—ABCB1—telencephalon—brain cancer	8.09e-05	0.0015	CbGeAlD
Methotrexate—Anaemia—Temozolomide—brain cancer	8.09e-05	0.000615	CcSEcCtD
Methotrexate—Diarrhoea—Procarbazine—brain cancer	8.08e-05	0.000615	CcSEcCtD
Methotrexate—Dyspepsia—Hydroxyurea—brain cancer	8.05e-05	0.000612	CcSEcCtD
Methotrexate—Decreased appetite—Hydroxyurea—brain cancer	7.95e-05	0.000604	CcSEcCtD
Methotrexate—Urinary tract disorder—Etoposide—brain cancer	7.94e-05	0.000604	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Hydroxyurea—brain cancer	7.89e-05	0.0006	CcSEcCtD
Methotrexate—Malaise—Temozolomide—brain cancer	7.89e-05	0.0006	CcSEcCtD
Methotrexate—Urethral disorder—Etoposide—brain cancer	7.88e-05	0.0006	CcSEcCtD
Methotrexate—Fatigue—Hydroxyurea—brain cancer	7.88e-05	0.000599	CcSEcCtD
Methotrexate—Vertigo—Temozolomide—brain cancer	7.86e-05	0.000598	CcSEcCtD
Methotrexate—Convulsion—Carmustine—brain cancer	7.84e-05	0.000597	CcSEcCtD
Methotrexate—Leukopenia—Temozolomide—brain cancer	7.83e-05	0.000596	CcSEcCtD
Methotrexate—Pain—Hydroxyurea—brain cancer	7.82e-05	0.000594	CcSEcCtD
Methotrexate—Dizziness—Procarbazine—brain cancer	7.81e-05	0.000594	CcSEcCtD
Methotrexate—Myalgia—Carmustine—brain cancer	7.71e-05	0.000586	CcSEcCtD
Methotrexate—Chest pain—Carmustine—brain cancer	7.71e-05	0.000586	CcSEcCtD
Methotrexate—Cough—Temozolomide—brain cancer	7.63e-05	0.000581	CcSEcCtD
Methotrexate—Erythema multiforme—Etoposide—brain cancer	7.6e-05	0.000578	CcSEcCtD
Methotrexate—Convulsion—Temozolomide—brain cancer	7.58e-05	0.000577	CcSEcCtD
Methotrexate—Feeling abnormal—Hydroxyurea—brain cancer	7.53e-05	0.000573	CcSEcCtD
Methotrexate—Eye disorder—Etoposide—brain cancer	7.52e-05	0.000572	CcSEcCtD
Methotrexate—Vomiting—Procarbazine—brain cancer	7.51e-05	0.000571	CcSEcCtD
Methotrexate—Cardiac disorder—Etoposide—brain cancer	7.46e-05	0.000568	CcSEcCtD
Methotrexate—Confusional state—Carmustine—brain cancer	7.45e-05	0.000567	CcSEcCtD
Methotrexate—Myalgia—Temozolomide—brain cancer	7.45e-05	0.000567	CcSEcCtD
Methotrexate—Arthralgia—Temozolomide—brain cancer	7.45e-05	0.000567	CcSEcCtD
Methotrexate—Rash—Procarbazine—brain cancer	7.45e-05	0.000566	CcSEcCtD
Methotrexate—Dermatitis—Procarbazine—brain cancer	7.44e-05	0.000566	CcSEcCtD
Methotrexate—ABCG2—brain—brain cancer	7.4e-05	0.00137	CbGeAlD
Methotrexate—Headache—Procarbazine—brain cancer	7.4e-05	0.000563	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	7.4e-05	0.000563	CcSEcCtD
Methotrexate—Discomfort—Temozolomide—brain cancer	7.36e-05	0.00056	CcSEcCtD
Methotrexate—Infection—Carmustine—brain cancer	7.34e-05	0.000558	CcSEcCtD
Methotrexate—Angiopathy—Etoposide—brain cancer	7.3e-05	0.000555	CcSEcCtD
Methotrexate—Immune system disorder—Etoposide—brain cancer	7.26e-05	0.000553	CcSEcCtD
Methotrexate—Mediastinal disorder—Etoposide—brain cancer	7.25e-05	0.000551	CcSEcCtD
Methotrexate—Thrombocytopenia—Carmustine—brain cancer	7.23e-05	0.00055	CcSEcCtD
Methotrexate—Body temperature increased—Hydroxyurea—brain cancer	7.23e-05	0.00055	CcSEcCtD
Methotrexate—Chills—Etoposide—brain cancer	7.22e-05	0.000549	CcSEcCtD
Methotrexate—Confusional state—Temozolomide—brain cancer	7.2e-05	0.000548	CcSEcCtD
Methotrexate—Anaphylactic shock—Temozolomide—brain cancer	7.14e-05	0.000543	CcSEcCtD
Methotrexate—Alopecia—Etoposide—brain cancer	7.11e-05	0.000541	CcSEcCtD
Methotrexate—Infection—Temozolomide—brain cancer	7.09e-05	0.00054	CcSEcCtD
Methotrexate—Anorexia—Carmustine—brain cancer	7.04e-05	0.000536	CcSEcCtD
Methotrexate—Nausea—Procarbazine—brain cancer	7.02e-05	0.000534	CcSEcCtD
Methotrexate—Nervous system disorder—Temozolomide—brain cancer	7e-05	0.000533	CcSEcCtD
Methotrexate—Thrombocytopenia—Temozolomide—brain cancer	6.99e-05	0.000532	CcSEcCtD
Methotrexate—Skin disorder—Temozolomide—brain cancer	6.94e-05	0.000528	CcSEcCtD
Methotrexate—Hypotension—Carmustine—brain cancer	6.9e-05	0.000525	CcSEcCtD
Methotrexate—Hyperhidrosis—Temozolomide—brain cancer	6.9e-05	0.000525	CcSEcCtD
Methotrexate—Dysgeusia—Etoposide—brain cancer	6.86e-05	0.000521	CcSEcCtD
Methotrexate—Anorexia—Temozolomide—brain cancer	6.81e-05	0.000518	CcSEcCtD
Methotrexate—Back pain—Etoposide—brain cancer	6.77e-05	0.000515	CcSEcCtD
Methotrexate—ABCB1—gonad—brain cancer	6.75e-05	0.00125	CbGeAlD
Methotrexate—Hypersensitivity—Hydroxyurea—brain cancer	6.73e-05	0.000512	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Carmustine—brain cancer	6.73e-05	0.000512	CcSEcCtD
Methotrexate—Insomnia—Carmustine—brain cancer	6.68e-05	0.000508	CcSEcCtD
Methotrexate—Paraesthesia—Carmustine—brain cancer	6.63e-05	0.000505	CcSEcCtD
Methotrexate—Dyspnoea—Carmustine—brain cancer	6.59e-05	0.000501	CcSEcCtD
Methotrexate—ABCB1—pituitary gland—brain cancer	6.58e-05	0.00122	CbGeAlD
Methotrexate—Somnolence—Carmustine—brain cancer	6.57e-05	0.0005	CcSEcCtD
Methotrexate—Asthenia—Hydroxyurea—brain cancer	6.56e-05	0.000499	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Temozolomide—brain cancer	6.51e-05	0.000495	CcSEcCtD
Methotrexate—Ill-defined disorder—Etoposide—brain cancer	6.5e-05	0.000494	CcSEcCtD
Methotrexate—Anaemia—Etoposide—brain cancer	6.47e-05	0.000492	CcSEcCtD
Methotrexate—Insomnia—Temozolomide—brain cancer	6.46e-05	0.000491	CcSEcCtD
Methotrexate—Decreased appetite—Carmustine—brain cancer	6.42e-05	0.000489	CcSEcCtD
Methotrexate—Paraesthesia—Temozolomide—brain cancer	6.41e-05	0.000488	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Carmustine—brain cancer	6.38e-05	0.000485	CcSEcCtD
Methotrexate—Dyspnoea—Temozolomide—brain cancer	6.37e-05	0.000484	CcSEcCtD
Methotrexate—ABCB1—medulla oblongata—brain cancer	6.35e-05	0.00118	CbGeAlD
Methotrexate—Somnolence—Temozolomide—brain cancer	6.35e-05	0.000483	CcSEcCtD
Methotrexate—Pain—Carmustine—brain cancer	6.32e-05	0.000481	CcSEcCtD
Methotrexate—Malaise—Etoposide—brain cancer	6.31e-05	0.00048	CcSEcCtD
Methotrexate—Vertigo—Etoposide—brain cancer	6.29e-05	0.000478	CcSEcCtD
Methotrexate—Dyspepsia—Temozolomide—brain cancer	6.29e-05	0.000478	CcSEcCtD
Methotrexate—Leukopenia—Etoposide—brain cancer	6.27e-05	0.000477	CcSEcCtD
Methotrexate—Diarrhoea—Hydroxyurea—brain cancer	6.25e-05	0.000476	CcSEcCtD
Methotrexate—Decreased appetite—Temozolomide—brain cancer	6.21e-05	0.000472	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Temozolomide—brain cancer	6.16e-05	0.000469	CcSEcCtD
Methotrexate—Fatigue—Temozolomide—brain cancer	6.16e-05	0.000468	CcSEcCtD
Methotrexate—Cough—Etoposide—brain cancer	6.11e-05	0.000465	CcSEcCtD
Methotrexate—Pain—Temozolomide—brain cancer	6.11e-05	0.000464	CcSEcCtD
Methotrexate—Feeling abnormal—Carmustine—brain cancer	6.09e-05	0.000463	CcSEcCtD
Methotrexate—Convulsion—Etoposide—brain cancer	6.07e-05	0.000461	CcSEcCtD
Methotrexate—Dizziness—Hydroxyurea—brain cancer	6.04e-05	0.00046	CcSEcCtD
Methotrexate—Gastrointestinal pain—Carmustine—brain cancer	6.04e-05	0.00046	CcSEcCtD
Methotrexate—Chest pain—Etoposide—brain cancer	5.96e-05	0.000453	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	5.92e-05	0.00045	CcSEcCtD
Methotrexate—Discomfort—Etoposide—brain cancer	5.89e-05	0.000448	CcSEcCtD
Methotrexate—Feeling abnormal—Temozolomide—brain cancer	5.88e-05	0.000448	CcSEcCtD
Methotrexate—Body temperature increased—Carmustine—brain cancer	5.84e-05	0.000444	CcSEcCtD
Methotrexate—Abdominal pain—Carmustine—brain cancer	5.84e-05	0.000444	CcSEcCtD
Methotrexate—Gastrointestinal pain—Temozolomide—brain cancer	5.84e-05	0.000444	CcSEcCtD
Methotrexate—Vomiting—Hydroxyurea—brain cancer	5.81e-05	0.000442	CcSEcCtD
Methotrexate—ABCB1—midbrain—brain cancer	5.81e-05	0.00108	CbGeAlD
Methotrexate—Rash—Hydroxyurea—brain cancer	5.76e-05	0.000438	CcSEcCtD
Methotrexate—Confusional state—Etoposide—brain cancer	5.76e-05	0.000438	CcSEcCtD
Methotrexate—Dermatitis—Hydroxyurea—brain cancer	5.76e-05	0.000438	CcSEcCtD
Methotrexate—Headache—Hydroxyurea—brain cancer	5.73e-05	0.000436	CcSEcCtD
Methotrexate—Anaphylactic shock—Etoposide—brain cancer	5.71e-05	0.000435	CcSEcCtD
Methotrexate—Infection—Etoposide—brain cancer	5.68e-05	0.000432	CcSEcCtD
Methotrexate—Urticaria—Temozolomide—brain cancer	5.67e-05	0.000431	CcSEcCtD
Methotrexate—ABCB1—spinal cord—brain cancer	5.67e-05	0.00105	CbGeAlD
Methotrexate—Abdominal pain—Temozolomide—brain cancer	5.64e-05	0.000429	CcSEcCtD
Methotrexate—Body temperature increased—Temozolomide—brain cancer	5.64e-05	0.000429	CcSEcCtD
Methotrexate—Thrombocytopenia—Etoposide—brain cancer	5.59e-05	0.000425	CcSEcCtD
Methotrexate—Skin disorder—Etoposide—brain cancer	5.55e-05	0.000422	CcSEcCtD
Methotrexate—Hyperhidrosis—Etoposide—brain cancer	5.52e-05	0.00042	CcSEcCtD
Methotrexate—Anorexia—Etoposide—brain cancer	5.45e-05	0.000414	CcSEcCtD
Methotrexate—Hypersensitivity—Carmustine—brain cancer	5.44e-05	0.000414	CcSEcCtD
Methotrexate—Nausea—Hydroxyurea—brain cancer	5.43e-05	0.000413	CcSEcCtD
Methotrexate—Hypotension—Etoposide—brain cancer	5.34e-05	0.000406	CcSEcCtD
Methotrexate—Asthenia—Carmustine—brain cancer	5.3e-05	0.000403	CcSEcCtD
Methotrexate—Hypersensitivity—Temozolomide—brain cancer	5.26e-05	0.0004	CcSEcCtD
Methotrexate—Paraesthesia—Etoposide—brain cancer	5.13e-05	0.00039	CcSEcCtD
Methotrexate—Asthenia—Temozolomide—brain cancer	5.12e-05	0.00039	CcSEcCtD
Methotrexate—ABCB1—endocrine gland—brain cancer	5.1e-05	0.000947	CbGeAlD
Methotrexate—Dyspnoea—Etoposide—brain cancer	5.09e-05	0.000387	CcSEcCtD
Methotrexate—Somnolence—Etoposide—brain cancer	5.08e-05	0.000386	CcSEcCtD
Methotrexate—Diarrhoea—Carmustine—brain cancer	5.06e-05	0.000385	CcSEcCtD
Methotrexate—Pruritus—Temozolomide—brain cancer	5.05e-05	0.000384	CcSEcCtD
Methotrexate—ABCB1—head—brain cancer	5.04e-05	0.000935	CbGeAlD
Methotrexate—Decreased appetite—Etoposide—brain cancer	4.97e-05	0.000378	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Etoposide—brain cancer	4.93e-05	0.000375	CcSEcCtD
Methotrexate—Fatigue—Etoposide—brain cancer	4.93e-05	0.000375	CcSEcCtD
Methotrexate—Dizziness—Carmustine—brain cancer	4.89e-05	0.000372	CcSEcCtD
Methotrexate—Pain—Etoposide—brain cancer	4.89e-05	0.000372	CcSEcCtD
Methotrexate—Diarrhoea—Temozolomide—brain cancer	4.89e-05	0.000372	CcSEcCtD
Methotrexate—Dizziness—Temozolomide—brain cancer	4.72e-05	0.000359	CcSEcCtD
Methotrexate—Feeling abnormal—Etoposide—brain cancer	4.71e-05	0.000358	CcSEcCtD
Methotrexate—Vomiting—Carmustine—brain cancer	4.7e-05	0.000357	CcSEcCtD
Methotrexate—Gastrointestinal pain—Etoposide—brain cancer	4.67e-05	0.000355	CcSEcCtD
Methotrexate—Rash—Carmustine—brain cancer	4.66e-05	0.000354	CcSEcCtD
Methotrexate—Dermatitis—Carmustine—brain cancer	4.65e-05	0.000354	CcSEcCtD
Methotrexate—Headache—Carmustine—brain cancer	4.63e-05	0.000352	CcSEcCtD
Methotrexate—ABCB1—central nervous system—brain cancer	4.6e-05	0.000853	CbGeAlD
Methotrexate—Vomiting—Temozolomide—brain cancer	4.54e-05	0.000345	CcSEcCtD
Methotrexate—Urticaria—Etoposide—brain cancer	4.54e-05	0.000345	CcSEcCtD
Methotrexate—Body temperature increased—Etoposide—brain cancer	4.52e-05	0.000344	CcSEcCtD
Methotrexate—Abdominal pain—Etoposide—brain cancer	4.52e-05	0.000344	CcSEcCtD
Methotrexate—Rash—Temozolomide—brain cancer	4.5e-05	0.000342	CcSEcCtD
Methotrexate—Dermatitis—Temozolomide—brain cancer	4.5e-05	0.000342	CcSEcCtD
Methotrexate—ABCB1—cerebellum—brain cancer	4.49e-05	0.000834	CbGeAlD
Methotrexate—Headache—Temozolomide—brain cancer	4.47e-05	0.00034	CcSEcCtD
Methotrexate—Nausea—Carmustine—brain cancer	4.39e-05	0.000334	CcSEcCtD
Methotrexate—Nausea—Temozolomide—brain cancer	4.24e-05	0.000323	CcSEcCtD
Methotrexate—Hypersensitivity—Etoposide—brain cancer	4.21e-05	0.00032	CcSEcCtD
Methotrexate—Asthenia—Etoposide—brain cancer	4.1e-05	0.000312	CcSEcCtD
Methotrexate—Pruritus—Etoposide—brain cancer	4.04e-05	0.000307	CcSEcCtD
Methotrexate—Diarrhoea—Etoposide—brain cancer	3.91e-05	0.000297	CcSEcCtD
Methotrexate—Dizziness—Etoposide—brain cancer	3.78e-05	0.000287	CcSEcCtD
Methotrexate—ABCB1—brain—brain cancer	3.65e-05	0.000677	CbGeAlD
Methotrexate—Vomiting—Etoposide—brain cancer	3.63e-05	0.000276	CcSEcCtD
Methotrexate—Rash—Etoposide—brain cancer	3.6e-05	0.000274	CcSEcCtD
Methotrexate—Dermatitis—Etoposide—brain cancer	3.6e-05	0.000274	CcSEcCtD
Methotrexate—Headache—Etoposide—brain cancer	3.58e-05	0.000272	CcSEcCtD
Methotrexate—Nausea—Etoposide—brain cancer	3.39e-05	0.000258	CcSEcCtD
Methotrexate—ABCC4—Ectoderm Differentiation—CTNNB1—brain cancer	2.54e-05	0.000647	CbGpPWpGaD
Methotrexate—PGD—Disease—VAV1—brain cancer	2.53e-05	0.000646	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—BSG—brain cancer	2.53e-05	0.000645	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—PCNA—brain cancer	2.53e-05	0.000644	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	2.52e-05	0.000641	CbGpPWpGaD
Methotrexate—SLC22A8—Transmembrane transport of small molecules—TRPC6—brain cancer	2.51e-05	0.00064	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—brain cancer	2.49e-05	0.000635	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—CCNE1—brain cancer	2.49e-05	0.000634	CbGpPWpGaD
Methotrexate—DHFR—Disease—HEY1—brain cancer	2.47e-05	0.000628	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—IDH1—brain cancer	2.45e-05	0.000625	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—TRPC6—brain cancer	2.44e-05	0.000622	CbGpPWpGaD
Methotrexate—DHFR—Disease—DLL1—brain cancer	2.42e-05	0.000616	CbGpPWpGaD
Methotrexate—ABCC4—Transmembrane transport of small molecules—TRPC6—brain cancer	2.41e-05	0.000613	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—IDH1—brain cancer	2.39e-05	0.00061	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—RELA—brain cancer	2.39e-05	0.000608	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—CYP2C9—brain cancer	2.39e-05	0.000608	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—HES1—brain cancer	2.38e-05	0.000607	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—brain cancer	2.36e-05	0.000602	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—S100A10—brain cancer	2.36e-05	0.000601	CbGpPWpGaD
Methotrexate—MTHFR—Disease—SHH—brain cancer	2.31e-05	0.00059	CbGpPWpGaD
Methotrexate—MTHFR—Disease—ENO2—brain cancer	2.31e-05	0.00059	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—BSG—brain cancer	2.31e-05	0.000588	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—BRCA2—brain cancer	2.3e-05	0.000585	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—PDGFRA—brain cancer	2.27e-05	0.000578	CbGpPWpGaD
Methotrexate—AOX1—Disease—ENO2—brain cancer	2.26e-05	0.000576	CbGpPWpGaD
Methotrexate—AOX1—Disease—SHH—brain cancer	2.26e-05	0.000576	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—PCNA—brain cancer	2.26e-05	0.000576	CbGpPWpGaD
Methotrexate—FPGS—Disease—APC—brain cancer	2.26e-05	0.000575	CbGpPWpGaD
Methotrexate—SLCO1A2—Transmembrane transport of small molecules—TRPC6—brain cancer	2.23e-05	0.000568	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—CCNE1—brain cancer	2.23e-05	0.000567	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—PIK3CG—brain cancer	2.22e-05	0.000567	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	2.22e-05	0.000565	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—BSG—brain cancer	2.21e-05	0.000563	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—PCNA—brain cancer	2.21e-05	0.000562	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HES5—brain cancer	2.19e-05	0.000557	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—CDK4—brain cancer	2.18e-05	0.000557	CbGpPWpGaD
Methotrexate—PGD—Disease—HES1—brain cancer	2.18e-05	0.000555	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—IDH1—brain cancer	2.18e-05	0.000555	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CYP2C9—brain cancer	2.15e-05	0.000548	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—IL2—brain cancer	2.15e-05	0.000548	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—TRPC6—brain cancer	2.1e-05	0.000534	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—VAV1—brain cancer	2.08e-05	0.000531	CbGpPWpGaD
Methotrexate—PGD—Disease—PDGFRA—brain cancer	2.08e-05	0.000529	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—S100A10—brain cancer	2.07e-05	0.000527	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—ERBB2—brain cancer	2.06e-05	0.000525	CbGpPWpGaD
Methotrexate—ABCC4—Ectoderm Differentiation—MYC—brain cancer	2.06e-05	0.000524	CbGpPWpGaD
Methotrexate—DHFR—Disease—ENO2—brain cancer	2.06e-05	0.000524	CbGpPWpGaD
Methotrexate—DHFR—Disease—SHH—brain cancer	2.06e-05	0.000524	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	2.06e-05	0.000524	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	2.04e-05	0.00052	CbGpPWpGaD
Methotrexate—ABCC2—Transmembrane transport of small molecules—TRPC6—brain cancer	2.03e-05	0.000517	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—BSG—brain cancer	2.03e-05	0.000517	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—TRPC6—brain cancer	2.01e-05	0.000511	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—brain cancer	2e-05	0.000508	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	2e-05	0.000508	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—IRS2—brain cancer	1.99e-05	0.000507	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—IDH1—brain cancer	1.98e-05	0.000505	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—PCNA—brain cancer	1.97e-05	0.000502	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—CDK4—brain cancer	1.95e-05	0.000498	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—ENO2—brain cancer	1.94e-05	0.000494	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—BSG—brain cancer	1.92e-05	0.000489	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—TRPC6—brain cancer	1.91e-05	0.000486	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—CDK4—brain cancer	1.91e-05	0.000486	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—IDH1—brain cancer	1.9e-05	0.000484	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—RELA—brain cancer	1.9e-05	0.000483	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—ENO2—brain cancer	1.89e-05	0.000482	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—PIK3CG—brain cancer	1.89e-05	0.000482	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—PIK3CG—brain cancer	1.89e-05	0.000482	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CYP2C9—brain cancer	1.87e-05	0.000477	CbGpPWpGaD
Methotrexate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—brain cancer	1.87e-05	0.000476	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—BSG—brain cancer	1.83e-05	0.000466	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—VAV1—brain cancer	1.83e-05	0.000466	CbGpPWpGaD
Methotrexate—PGD—Disease—IRS2—brain cancer	1.82e-05	0.000464	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—IL2—brain cancer	1.81e-05	0.00046	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—CTNNB1—brain cancer	1.8e-05	0.00046	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—PIK3CG—brain cancer	1.77e-05	0.000452	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—TRPC6—brain cancer	1.77e-05	0.00045	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—APC—brain cancer	1.76e-05	0.000448	CbGpPWpGaD
Methotrexate—FPGS—Disease—ERBB2—brain cancer	1.75e-05	0.000447	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—IDH1—brain cancer	1.74e-05	0.000444	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—ENO2—brain cancer	1.72e-05	0.000439	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—CDK4—brain cancer	1.7e-05	0.000434	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CYP2C9—brain cancer	1.69e-05	0.00043	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	1.68e-05	0.000427	CbGpPWpGaD
Methotrexate—MTHFR—Disease—VAV1—brain cancer	1.67e-05	0.000426	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—CDKN2A—brain cancer	1.67e-05	0.000425	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—brain cancer	1.64e-05	0.000417	CbGpPWpGaD
Methotrexate—AOX1—Disease—VAV1—brain cancer	1.63e-05	0.000416	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—IL2—brain cancer	1.63e-05	0.000415	CbGpPWpGaD
Methotrexate—PGD—Disease—APC—brain cancer	1.61e-05	0.00041	CbGpPWpGaD
Methotrexate—TYMS—Circadian rythm related genes—TP53—brain cancer	1.61e-05	0.00041	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—SIRT1—brain cancer	1.61e-05	0.000409	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CYP2C9—brain cancer	1.6e-05	0.000408	CbGpPWpGaD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—VEGFA—brain cancer	1.6e-05	0.000408	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—BSG—brain cancer	1.59e-05	0.000406	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—brain cancer	1.59e-05	0.000404	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—IDH1—brain cancer	1.57e-05	0.000401	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—STAT3—brain cancer	1.57e-05	0.000401	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—ENO2—brain cancer	1.57e-05	0.0004	CbGpPWpGaD
Methotrexate—ALB—Platelet degranulation—VEGFA—brain cancer	1.57e-05	0.000399	CbGpPWpGaD
Methotrexate—ABCC4—Platelet activation, signaling and aggregation—VEGFA—brain cancer	1.54e-05	0.000391	CbGpPWpGaD
Methotrexate—FPGS—Disease—CTNNB1—brain cancer	1.53e-05	0.000391	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—IDH1—brain cancer	1.5e-05	0.000383	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—ENO2—brain cancer	1.5e-05	0.000383	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—CDKN2A—brain cancer	1.49e-05	0.00038	CbGpPWpGaD
Methotrexate—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—brain cancer	1.49e-05	0.00038	CbGpPWpGaD
Methotrexate—DHFR—Disease—VAV1—brain cancer	1.49e-05	0.000378	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP2C9—brain cancer	1.48e-05	0.000378	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—brain cancer	1.48e-05	0.000376	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—PIK3CG—brain cancer	1.47e-05	0.000375	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IDH1—brain cancer	1.47e-05	0.000375	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—MYC—brain cancer	1.46e-05	0.000372	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—CDKN2A—brain cancer	1.46e-05	0.000371	CbGpPWpGaD
Methotrexate—MTHFR—Disease—HES1—brain cancer	1.44e-05	0.000366	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—BSG—brain cancer	1.43e-05	0.000365	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—EGFR—brain cancer	1.43e-05	0.000364	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.42e-05	0.000362	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—CCND1—brain cancer	1.41e-05	0.000359	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—brain cancer	1.41e-05	0.000358	CbGpPWpGaD
Methotrexate—AOX1—Disease—HES1—brain cancer	1.4e-05	0.000358	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HEY1—brain cancer	1.4e-05	0.000356	CbGpPWpGaD
Methotrexate—ABCB1—Allograft Rejection—VEGFA—brain cancer	1.39e-05	0.000353	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—TP53—brain cancer	1.38e-05	0.000352	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—ENO2—brain cancer	1.38e-05	0.000351	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—IDH1—brain cancer	1.37e-05	0.000349	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PDGFRA—brain cancer	1.37e-05	0.000349	CbGpPWpGaD
Methotrexate—ABCC1—Disease—DLL1—brain cancer	1.37e-05	0.000349	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—ERBB2—brain cancer	1.37e-05	0.000348	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—BSG—brain cancer	1.36e-05	0.000347	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PIK3CG—brain cancer	1.35e-05	0.000343	CbGpPWpGaD
Methotrexate—AOX1—Disease—PDGFRA—brain cancer	1.34e-05	0.000341	CbGpPWpGaD
Methotrexate—FPGS—Disease—STAT3—brain cancer	1.34e-05	0.000341	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—PIK3CG—brain cancer	1.32e-05	0.000337	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—CDKN2A—brain cancer	1.3e-05	0.000332	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.28e-05	0.000326	CbGpPWpGaD
Methotrexate—DHFR—Disease—HES1—brain cancer	1.28e-05	0.000325	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—BSG—brain cancer	1.26e-05	0.000321	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—CCND1—brain cancer	1.26e-05	0.000321	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TRPC6—brain cancer	1.26e-05	0.000321	CbGpPWpGaD
Methotrexate—PGD—Disease—ERBB2—brain cancer	1.25e-05	0.000318	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—IL2—brain cancer	1.25e-05	0.000318	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ENO2—brain cancer	1.24e-05	0.000317	CbGpPWpGaD
Methotrexate—FPGS—Disease—MYC—brain cancer	1.24e-05	0.000317	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—IDH1—brain cancer	1.23e-05	0.000314	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—CCND1—brain cancer	1.23e-05	0.000314	CbGpPWpGaD
Methotrexate—DHFR—Disease—PDGFRA—brain cancer	1.22e-05	0.00031	CbGpPWpGaD
Methotrexate—FPGS—Disease—EGFR—brain cancer	1.22e-05	0.00031	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—brain cancer	1.22e-05	0.00031	CbGpPWpGaD
Methotrexate—MTHFR—Disease—IRS2—brain cancer	1.2e-05	0.000306	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—CTNNB1—brain cancer	1.2e-05	0.000304	CbGpPWpGaD
Methotrexate—AOX1—Disease—IRS2—brain cancer	1.17e-05	0.000299	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—IDH1—brain cancer	1.17e-05	0.000298	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SHH—brain cancer	1.16e-05	0.000296	CbGpPWpGaD
Methotrexate—ABCC1—Disease—ENO2—brain cancer	1.16e-05	0.000296	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—PIK3CG—brain cancer	1.16e-05	0.000296	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—APC—brain cancer	1.14e-05	0.000291	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—MYC—brain cancer	1.13e-05	0.000288	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.12e-05	0.000284	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—CCND1—brain cancer	1.1e-05	0.00028	CbGpPWpGaD
Methotrexate—PGD—Disease—CTNNB1—brain cancer	1.09e-05	0.000278	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—TRPC6—brain cancer	1.09e-05	0.000278	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—IDH1—brain cancer	1.09e-05	0.000276	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ENO2—brain cancer	1.08e-05	0.000276	CbGpPWpGaD
Methotrexate—DHFR—Disease—IRS2—brain cancer	1.07e-05	0.000272	CbGpPWpGaD
Methotrexate—MTHFR—Disease—APC—brain cancer	1.06e-05	0.00027	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—VEGFA—brain cancer	1.06e-05	0.00027	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—STAT3—brain cancer	1.04e-05	0.000265	CbGpPWpGaD
Methotrexate—AOX1—Disease—APC—brain cancer	1.04e-05	0.000264	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—MYC—brain cancer	1.01e-05	0.000258	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1e-05	0.000256	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—MYC—brain cancer	9.88e-06	0.000252	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ENO2—brain cancer	9.75e-06	0.000248	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—MYC—brain cancer	9.68e-06	0.000247	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—TRPC6—brain cancer	9.55e-06	0.000243	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	9.54e-06	0.000243	CbGpPWpGaD
Methotrexate—PGD—Disease—STAT3—brain cancer	9.53e-06	0.000243	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—EGFR—brain cancer	9.47e-06	0.000241	CbGpPWpGaD
Methotrexate—DHFR—Disease—APC—brain cancer	9.43e-06	0.00024	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VAV1—brain cancer	9.43e-06	0.00024	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—IL2—brain cancer	9.31e-06	0.000237	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ENO2—brain cancer	9.26e-06	0.000236	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP2C9—brain cancer	9.16e-06	0.000233	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PIK3CG—brain cancer	8.89e-06	0.000226	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	8.88e-06	0.000226	CbGpPWpGaD
Methotrexate—PGD—Disease—MYC—brain cancer	8.85e-06	0.000226	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—MYC—brain cancer	8.83e-06	0.000225	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PIK3CG—brain cancer	8.68e-06	0.000221	CbGpPWpGaD
Methotrexate—PGD—Disease—EGFR—brain cancer	8.66e-06	0.000221	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ENO2—brain cancer	8.58e-06	0.000218	CbGpPWpGaD
Methotrexate—ABCC1—Disease—VAV1—brain cancer	8.41e-06	0.000214	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—TP53—brain cancer	8.31e-06	0.000212	CbGpPWpGaD
Methotrexate—MTHFR—Disease—ERBB2—brain cancer	8.24e-06	0.00021	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—IL2—brain cancer	8.17e-06	0.000208	CbGpPWpGaD
Methotrexate—AOX1—Disease—ERBB2—brain cancer	8.05e-06	0.000205	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP2C9—brain cancer	8.02e-06	0.000204	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—TP53—brain cancer	8.02e-06	0.000204	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—VEGFA—brain cancer	7.91e-06	0.000202	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PIK3CG—brain cancer	7.9e-06	0.000201	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	7.85e-06	0.0002	CbGpPWpGaD
Methotrexate—ALB—Metabolism—BSG—brain cancer	7.79e-06	0.000198	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	7.77e-06	0.000198	CbGpPWpGaD
Methotrexate—DHFR—Disease—ERBB2—brain cancer	7.33e-06	0.000187	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—TP53—brain cancer	7.25e-06	0.000185	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HES1—brain cancer	7.23e-06	0.000184	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CTNNB1—brain cancer	7.21e-06	0.000184	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CG—brain cancer	7.2e-06	0.000183	CbGpPWpGaD
Methotrexate—AOX1—Disease—CTNNB1—brain cancer	7.04e-06	0.000179	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—VEGFA—brain cancer	6.95e-06	0.000177	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CG—brain cancer	6.89e-06	0.000176	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PDGFRA—brain cancer	6.89e-06	0.000175	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	6.84e-06	0.000174	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—BSG—brain cancer	6.82e-06	0.000174	CbGpPWpGaD
Methotrexate—ALB—Metabolism—IDH1—brain cancer	6.7e-06	0.000171	CbGpPWpGaD
Methotrexate—DHFR—Disease—CTNNB1—brain cancer	6.41e-06	0.000163	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CG—brain cancer	6.32e-06	0.000161	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	6.29e-06	0.00016	CbGpPWpGaD
Methotrexate—MTHFR—Disease—STAT3—brain cancer	6.29e-06	0.00016	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	6.16e-06	0.000157	CbGpPWpGaD
Methotrexate—AOX1—Disease—STAT3—brain cancer	6.14e-06	0.000156	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IRS2—brain cancer	6.05e-06	0.000154	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CG—brain cancer	5.99e-06	0.000153	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TP53—brain cancer	5.98e-06	0.000152	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—IDH1—brain cancer	5.87e-06	0.000149	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MYC—brain cancer	5.84e-06	0.000149	CbGpPWpGaD
Methotrexate—MTHFR—Disease—EGFR—brain cancer	5.71e-06	0.000146	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CG—brain cancer	5.71e-06	0.000145	CbGpPWpGaD
Methotrexate—AOX1—Disease—MYC—brain cancer	5.71e-06	0.000145	CbGpPWpGaD
Methotrexate—DHFR—Disease—STAT3—brain cancer	5.59e-06	0.000142	CbGpPWpGaD
Methotrexate—AOX1—Disease—EGFR—brain cancer	5.58e-06	0.000142	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	5.45e-06	0.000139	CbGpPWpGaD
Methotrexate—ABCC1—Disease—APC—brain cancer	5.34e-06	0.000136	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ENO2—brain cancer	5.29e-06	0.000135	CbGpPWpGaD
Methotrexate—DHFR—Disease—MYC—brain cancer	5.19e-06	0.000132	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	5.17e-06	0.000132	CbGpPWpGaD
Methotrexate—DHFR—Disease—EGFR—brain cancer	5.08e-06	0.000129	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CG—brain cancer	4.97e-06	0.000127	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ENO2—brain cancer	4.64e-06	0.000118	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CG—brain cancer	4.47e-06	0.000114	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CG—brain cancer	4.25e-06	0.000108	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IL2—brain cancer	4.21e-06	0.000107	CbGpPWpGaD
Methotrexate—ABCC1—Disease—ERBB2—brain cancer	4.15e-06	0.000106	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CG—brain cancer	3.93e-06	0.0001	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CTNNB1—brain cancer	3.63e-06	9.24e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VEGFA—brain cancer	3.58e-06	9.12e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—STAT3—brain cancer	3.16e-06	8.05e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MYC—brain cancer	2.94e-06	7.48e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EGFR—brain cancer	2.87e-06	7.32e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—brain cancer	2.71e-06	6.89e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CG—brain cancer	2.43e-06	6.18e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CG—brain cancer	2.13e-06	5.42e-05	CbGpPWpGaD
